You are here:
Company

Glycanscan

Back to overview

Glycanscan is a Groningen-based biotech company focused on early detection of diseases such as oesophageal cancer via glyco-biomarkers in blood samples. They are developing an innovative test that detects changes in sugar molecules (glycans) on proteins, which can provide clues to early-stage cancer.

Glycanscan belongs to the fund:

Pharma Connect Capital">

Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...

View all the funds from the IFG

Arches Capital is a fast growing group of business angels that is bridging the gap between Venture Capitalist (VCs) and...
Lumo Labs creates opportunities for impact-driven ventures in emerging technologies....